Diagnostics World | Researchers at The University of Texas MD Anderson Cancer Center are investigating whether immune-system biomarkers could help identify cancer patients most likely to benefit from rapid-acting psychedelic treatments for depression. Researchers examined whether these rapid-acting antidepressants share biological pathways that could serve as biomarkers for future treatment strategies.
